Safety of treatments for primary Sjögren's syndrome.

about

Clinical Efficacy and Safety of Total Glucosides of Paeony for Primary Sjögren's Syndrome: A Systematic Review.Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?

P2860

Q33794924-9457D1AA-025F-4034-A9CD-C5BE270299EA Q54384919-73F231A1-0E50-48D0-8FA8-2119B85D5C7B

P2860

Safety of treatments for primary Sjögren's syndrome.

Item

http://www.wikidata.org/entity/Q38711144

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Safety of treatments for primary Sjögren's syndrome.

@en

type

Item

label

Safety of treatments for primary Sjögren's syndrome.

@en

prefLabel

Safety of treatments for primary Sjögren's syndrome.

@en

P1476

Safety of treatments for primary Sjögren's syndrome.

@en

P2093

Arjan Vissink

http://www.w3.org/2001/XMLSchema#string

Elisabeth Brouwer

http://www.w3.org/2001/XMLSchema#string

Hendrika Bootsma

http://www.w3.org/2001/XMLSchema#string

Jolien F van Nimwegen

http://www.w3.org/2001/XMLSchema#string

Nicole Sillevis Smitt

http://www.w3.org/2001/XMLSchema#string

Rada V Moerman

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis

Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study

Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

P304

513-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2016.1146676

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26809028

http://www.w3.org/2001/XMLSchema#string

Safety of treatments for primary Sjögren's syndrome.

about

P2860

P2860

Safety of treatments for primary Sjögren's syndrome.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698